• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Regular aspirin use does not reduce risk of incident cognitive decline (P7.117)
CONCLUSIONS: Regular aspirin did not provide a protective association against incident cognitive impairment in a large, biracial, and geographically diverse cohort. Study Supported by: This research project is supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service. Disclosure: Dr. Kelley has received personal compensation for activities with Eli Lilly & Co. as a consultant. Dr. McClure has received research support from Genzyme and Amgen. Dr. Unverzagt has received personal compensation...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Kelley, B., McClure, L., Unverzagt, F., Kissela, B., Kleindorfer, D., Howard, G., Wadley, V. Tags: Aging, Dementia, Cognitive, and Behavioral Neurology: Cardio- and Cerebrovascular Factors in Dementia Source Type: research

Under Affordable Care Act, Americans have had more preventive care for heart health, UCLA study finds
By reducing out-of-pocket costs for preventive treatment, the Affordable Care Act appears to have encouraged more people to have health screenings related to their cardiovascular health,a UCLA study found. Comparing figures from 2006 through 2013, researchers found that more people were screened for diabetes, high cholesterol, cigarette use and high blood pressure — all risk factors for heart disease — after the ACA was implemented than before.But the research, published in the peer-reviewed American Journal of Managed Care, also revealed a disparity between men and women in one key area. Although more men who are at r...
Source: UCLA Newsroom: Health Sciences - November 23, 2017 Category: Universities & Medical Training Source Type: news

Clinical Performance Measures that Matter —Are You Ready?
Conclusion The future will belong to those who can prove value. The use of a clinical performance dashboard and comparisons to national data will help to ensure that when the payers come knocking on our doors looking for "proof" that what we do enhances patient care and improves patient outcome, we’ll have an answer! This is the first in a yearlong series of articles developed by the Academy of International Mobile Healthcare Integration (AIMHI).The AIMHI article series is developed in partnership with JEMS to help educate EMS agencies on the hallmarks and attributes of high-performance/high-value EMS system de...
Source: JEMS Special Topics - December 11, 2018 Category: Emergency Medicine Authors: Wayne C. Harbour, NRP Tags: Exclusive Articles Operations Administration and Leadership Source Type: news

Every Little Anniversary
One of the things they tell you after they’ve informed you that you have cancer or that you’ve had a stroke—after they tell you about the resections and the radiation—after they tell you about the aspirin and the clopidogrel—after you’re stable medically but still more than a little unstable emotionally—is to look for a support group. I had the kind of cancer that you learn about in medical school and then never see. I was decades younger than most of my physicians’ patients with stroke. The local support groups didn’t seem to fit me. I looked online at first, but then—even though I found a few people w...
Source: JAMA - December 1, 2015 Category: Journals (General) Source Type: research

'Dying of heartache?' Heart problems linked to bereavement
Conclusion The study found that people were more likely to have AF for the first time in the weeks immediately after a bereavement, but that this raised risk does not last. Despite the headlines, this does not mean that anyone who's had a bereavement is at immediate risk of "dying of a broken heart". Atrial fibrillation is treatable and not usually life-threatening. Because this was an observational study, we cannot rule out the possibility that factors such as family history of atrial fibrillation or lifestyle factors could have affected the results, although the researcher's conclusion that this is a small poss...
Source: NHS News Feed - April 6, 2016 Category: Consumer Health News Tags: Heart/lungs Mental health Source Type: news

International Clinical Trials' Day 2016
International Clinical Trials' Day is celebrated around the world each year on or close to 20 May, commemorating the day in 1747 on which James Lind began the first known controlled trial, comparing different treatments for scurvy then in common use among sailors in the British Royal Navy. (Watch a video explaining the trial to see history in the making.) International Clinical Trials' Day seeks to raise awareness of the importance of research to health care, and draw attention to ways in which the research can become more relevant to practice.The European Clinical Research Infrastructures Network (ECRIN) helps to co-ordin...
Source: Cochrane News and Events - May 19, 2016 Category: Information Technology Authors: mumoquit at cochrane.org Source Type: news

After Moyamoya surgery, a back-to-normal birthday for Carolyn
Before Moyamoya surgery Carolyn Milks turns 8 on August 21. It’s a big celebration. Carolyn and her family aren’t just celebrating her birthday — they’re celebrating Carolyn’s return to normal. For most of the summer, things like swimming, riding her bicycle and horsing around with her sisters and cousins had been out of the question for Carolyn. But on August 11, Dr. Ed Smith, co-director of the Boston Children’s Hospital Cerebrovascular Surgery and Interventions Center, gave Carolyn the green light. She could go back to being a kid. “This is what kids really want. They just want to ...
Source: Thrive, Children's Hospital Boston - August 18, 2016 Category: Pediatrics Authors: Joyce Choi Tags: Our Patients’ Stories Boston Children's at Waltham Cerebrovascular Surgery and Interventions Center Dr. Ed Smith moyamoya Source Type: news

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Carrie Fisher's Death Highlights The Reality Of Heart Disease In Women
Carrie Fisher died early Tuesday morning, four days after suffering a heart attack on a flight from London to Los Angeles. The actress and author, best known for her iconic role as Princess Leia in the “Star Wars” franchise, was 60 years old.  Experts say that Fisher’s death highlights an important reality about heart disease: It is the leading cause of death among men and women alike in the U.S. While heart disease encompasses many different conditions, a heart attack occurs when coronary arteries become blocked and oxygenated blood can’t reach the heart. About 735,000 Americans have hea...
Source: Science - The Huffington Post - December 28, 2016 Category: Science Source Type: news

Pages: 1  2  3